Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker BNTC
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 29, 2025 | Aaron Cowen Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 11,587 | $13.44 | $155.7K Buy | Form 4 ↗ |
| Dec 29, 2025 | Aaron Cowen Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 65,800 | $13.44 | $884.4K Buy | Form 4 ↗ |
| Dec 26, 2025 | Aaron Cowen Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 2,516 | $13.10 | $33.0K Buy | Form 4 ↗ |
| Dec 26, 2025 | Aaron Cowen Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 14,320 | $13.10 | $187.6K Buy | Form 4 ↗ |
| Dec 23, 2025 | Aaron Cowen Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 7,400 | $12.85 | $95.1K Buy | Form 4 ↗ |
| Dec 23, 2025 | Aaron Cowen Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 42,600 | $12.85 | $547.4K Buy | Form 4 ↗ |
| Dec 22, 2025 | Averill Madison Master Fund, Ltd. 10% owner | BNTC Benitec Biopharma Inc. | Buy | 2,892 | $12.08 | $34.9K Buy | Form 4 ↗ |
| Dec 22, 2025 | Averill Madison Master Fund, Ltd. 10% owner | BNTC Benitec Biopharma Inc. | Buy | 16,650 | $12.08 | $201.1K Buy | Form 4 ↗ |
| Dec 19, 2025 | Averill Madison Master Fund, Ltd. 10% owner | BNTC Benitec Biopharma Inc. | Buy | 2,434 | $11.48 | $27.9K Buy | Form 4 ↗ |
| Dec 19, 2025 | Averill Madison Master Fund, Ltd. 10% owner | BNTC Benitec Biopharma Inc. | Buy | 13,950 | $11.48 | $160.1K Buy | Form 4 ↗ |
| Dec 18, 2025 | Averill Madison Master Fund, Ltd. 10% owner | BNTC Benitec Biopharma Inc. | Buy | 1,515 | $11.24 | $17.0K Buy | Form 4 ↗ |
| Dec 18, 2025 | Averill Madison Master Fund, Ltd. 10% owner | BNTC Benitec Biopharma Inc. | Buy | 8,700 | $11.24 | $97.8K Buy | Form 4 ↗ |
| Nov 7, 2025 | Suvretta Capital Management, LLC Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 751,111 | $13.50 | $10.1M Buy | Form 4 ↗ |
| Nov 7, 2025 | Suvretta Capital Management, LLC Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 730,370 | $13.50 | $9.9M Buy | Form 4 ↗ |
| Mar 31, 2025 | Suvretta Capital Management, LLC Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 670 | $13.22 | $8,857 Buy | Form 4 ↗ |
| Mar 31, 2025 | Suvretta Capital Management, LLC Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 5,057 | $13.22 | $66.9K Buy | Form 4 ↗ |
| Mar 31, 2025 | Suvretta Capital Management, LLC Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 1,267 | $12.63 | $16.0K Buy | Form 4 ↗ |
| Mar 31, 2025 | Suvretta Capital Management, LLC Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 9,503 | $12.63 | $120.0K Buy | Form 4 ↗ |
| Mar 26, 2025 | Aaron Cowen 10% owner | BNTC Benitec Biopharma Inc. | Buy | 106,200 | $13.00 | $1.4M Buy | Form 4 ↗ |
| Mar 26, 2025 | Aaron Cowen 10% owner | BNTC Benitec Biopharma Inc. | Buy | 793,800 | $13.00 | $10.3M Buy | Form 4 ↗ |
| Dec 24, 2024 | Aaron Cowen 10% owner | BNTC Benitec Biopharma Inc. | Buy | 2,288 | $11.25 | $25.7K Buy | Form 4 ↗ |
| Dec 24, 2024 | Aaron Cowen 10% owner | BNTC Benitec Biopharma Inc. | Buy | 17,730 | $11.25 | $199.5K Buy | Form 4 ↗ |
| Dec 23, 2024 | Aaron Cowen 10% owner | BNTC Benitec Biopharma Inc. | Buy | 3,142 | $10.98 | $34.5K Buy | Form 4 ↗ |
| Dec 23, 2024 | Aaron Cowen 10% owner | BNTC Benitec Biopharma Inc. | Buy | 24,360 | $10.98 | $267.5K Buy | Form 4 ↗ |
| Dec 3, 2024 | Suvretta Capital Management, LLC Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 4,810 | $9.60 | $46.2K Buy | Form 4 ↗ |
| Dec 3, 2024 | Suvretta Capital Management, LLC Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 37,190 | $9.60 | $357.0K Buy | Form 4 ↗ |
| Nov 20, 2024 | Averill Master Fund, Ltd. Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 3,076 | $10.22 | $31.4K Buy | Form 4 ↗ |
| Nov 20, 2024 | Averill Master Fund, Ltd. Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 24,360 | $10.22 | $249.0K Buy | Form 4 ↗ |
| Nov 19, 2024 | Averill Master Fund, Ltd. Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 1,570 | $9.73 | $15.3K Buy | Form 4 ↗ |
| Nov 19, 2024 | Averill Master Fund, Ltd. Director, 10% owner | BNTC Benitec Biopharma Inc. | Buy | 12,430 | $9.73 | $120.9K Buy | Form 4 ↗ |
30 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:39 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances